Get the Stockscreener App
1.20
2.56%
0.03
Soligenix Inc stock is traded at $1.20, with a volume of 109.88K.
It is up +2.56% in the last 24 hours and up +1.69% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.17
Open:
$1.18
24h Volume:
109.88K
Relative Volume:
0.54
Market Cap:
$12.10M
Revenue:
$200.00K
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.328
EPS:
-3.6582
Net Cash Flow:
$-9.76M
1W Performance:
-1.64%
1M Performance:
+1.69%
6M Performance:
-25.93%
1Y Performance:
-49.37%
1-Day Range:
$1.16
$1.20
1-Week Range:
$1.15
$1.2396
52-Week Range:
$1.02
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.20 | 11.80M | 200.00K | -11.46M | -9.76M | -3.6582 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - Benzinga
Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - Benzinga
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Nasdaq
HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Bitget
Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - Digital Journal
Soligenix (SNGX) Highlights HyBryte's Promise in Treating Early-Stage CTCL - GuruFocus
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - ChartMill
Soligenix's HyBryte Clinical Data Published in Peer-Reviewed Journal, Supporting Potential as First-Line CTCL Treatment - citybuzz -
Soligenix Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Total debt per share of Soligenix, Inc. – LSE:0A6I - TradingView
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease - USA Today
Earnings Risk: Should you avoid Soligenix Inc stock right now2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma
Soligenix receives UK regulatory designation for Behçet’s drug By Investing.com - Investing.com Canada
Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease - NewMediaWire
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - Lelezard
Soligenix receives UK regulatory designation for Behçet’s drug - Investing.com
Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment - GuruFocus
Soligenix Announces SGX945 Receives Promising Innovative Medicin - GuruFocus
Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach - NewMediaWire
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView
SNGX SEC FilingsSoligenix Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SNGX Earnings History & Surprises | EPS & Revenue Results | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behcet Disease - Digital Journal
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - Digital Journal
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Soligenix (SNGX) and Day One Biopharmaceuticals (DAWN) - The Globe and Mail
Soligenix receives positive EMA opinion for orphan drug status - Investing.com Australia
Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA). - Bitget
Soligenix receives positive EMA opinion for orphan drug status By Investing.com - Investing.com UK
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - Nasdaq
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease - The Globe and Mail
SNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Growth Value: Is Soligenix Inc a speculative investmentOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Soligenix to Present at BIO Investment Summit - Intellectia AI
Soligenix to Present at BIO Investment & Growth Summit - PR Newswire
SNGX PE Ratio & Valuation, Is SNGX Overvalued - Intellectia AI
Will Soligenix Inc. face regulatory challenges2025 Stock Rankings & Proven Capital Preservation Methods - mfd.ru
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Armistice Capital and Steven Boyd report 4.99% stake in Soligenix (SNGX) - Stock Titan
Why Soligenix Inc. stock is favored by top institutions2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Soligenix, Inc. Announces Adjournment of Annual Meeting, Informa - GuruFocus
Will Soligenix Inc. stock split attract more investors2025 Geopolitical Influence & AI Forecasted Stock Moves - mfd.ru
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX) - The Globe and Mail
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):